Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Outlook Therapeutics, Inc. (OTLK) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Outlook Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1649989.
Total stock buying since 2016: $33,309,700.
Total stock sales since 2016: $2,044,258.
Total stock option exercises since 2016: $1,755,530.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 783,651 | $76,921 | 0 | $0 | 0 | $0 |
| 2023 | 0 | $0 | 951,155 | $1,090,295 | 0 | $0 |
| 2022 | 343,968 | $477,926 | 0 | $0 | 0 | $0 |
| 2021 | 27,523,401 | $31,598,694 | 145,127 | $358,775 | 0 | $0 |
| 2020 | 853,045 | $1,020,179 | 0 | $0 | 34,016,473 | $1,080,621 |
| 2019 | 145,731 | $106,316 | 1,350 | $2,295 | 5,090,909 | $674,909 |
| 2018 | 49,416 | $29,664 | 132,477 | $149,380 | 0 | $0 |
| 2017 | 0 | $0 | 195,996 | $223,251 | 0 | $0 |
| 2016 | 2,000 | $0 | 58,737 | $220,262 | 405,796 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-09 | 5,000 | $28,445 | 0 | $0 | 0 | $0 |
| 2024-04 | 714,286 | $0 | 0 | $0 | 0 | $0 |
| 2024-03 | 64,365 | $48,476 | 0 | $0 | 0 | $0 |
| 2023-04 | 0 | $0 | 520,000 | $590,200 | 0 | $0 |
| 2023-01 | 0 | $0 | 431,155 | $500,095 | 0 | $0 |
| 2022-10 | 111,203 | $142,511 | 0 | $0 | 0 | $0 |
| 2022-06 | 29,925 | $31,620 | 0 | $0 | 0 | $0 |
| 2022-03 | 27,708 | $46,826 | 0 | $0 | 0 | $0 |
| 2022-02 | 175,132 | $256,969 | 0 | $0 | 0 | $0 |
| 2021-12 | 133,401 | $183,994 | 0 | $0 | 0 | $0 |
| 2021-11 | 16,000,000 | $20,000,000 | 0 | $0 | 0 | $0 |
| 2021-04 | 30,000 | $54,700 | 0 | $0 | 0 | $0 |
| 2021-02 | 11,360,000 | $11,360,000 | 145,127 | $358,775 | 0 | $0 |
| 2020-09 | 30,000 | $20,180 | 0 | $0 | 0 | $0 |
| 2020-07 | 823,045 | $999,999 | 0 | $0 | 0 | $0 |
| 2020-03 | 0 | $0 | 0 | $0 | 29,358,621 | $0 |
| 2020-01 | 0 | $0 | 0 | $0 | 4,657,852 | $1,080,621 |
| 2019-12 | 0 | $0 | 0 | $0 | 2,909,091 | $674,909 |
| 2019-09 | 0 | $0 | 1,350 | $2,295 | 0 | $0 |
| 2019-06 | 0 | $0 | 0 | $0 | 2,181,818 | $0 |
| 2019-02 | 39,183 | $33,475 | 0 | $0 | 0 | $0 |
| 2019-01 | 106,548 | $72,841 | 0 | $0 | 0 | $0 |
| 2018-12 | 49,416 | $29,664 | 0 | $0 | 0 | $0 |
| 2018-09 | 0 | $0 | 10,100 | $8,807 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-09-26 | Kenyon Lawrence A (Chief Financial Officer) | Buy | 5,000 | 5.69 | 28,445 |
| 2024-04-15 | Syntone Ventures Llc | Buy | 714,286 | .00 | 0 |
| 2024-03-28 | Haddadin Yezan Munther | Buy | 1,881 | 11.82 | 22,233 |
| 2024-03-07 | Evanson Jeff (CHIEF COMMERCIAL OFFICER) | Buy | 62,484 | .42 | 26,243 |
| 2023-04-20 | Dagnon Terry (Chief Operations Officer) | Sale | 520,000 | 1.14 | 590,200 |
| 2023-01-20 | Evanson Jeff (Chief Commercial Officer) | Sale | 267,000 | 1.11 | 296,370 |
| 2023-01-19 | Evanson Jeff (Chief Commercial Officer) | Sale | 103,255 | 1.22 | 125,971 |
| 2023-01-18 | Evanson Jeff (Chief Commercial Officer) | Sale | 33,738 | 1.25 | 42,172 |
| 2023-01-17 | Evanson Jeff (Chief Commercial Officer) | Sale | 27,162 | 1.31 | 35,582 |
| 2022-10-05 | Hilzinger Kurt J (Director) | Buy | 15,662 | 1.23 | 19,264 |
| 2022-10-04 | Hilzinger Kurt J (Director) | Buy | 95,541 | 1.29 | 123,247 |
| 2022-06-21 | Dagnon Terry (Chief Operating Officer) | Buy | 10,000 | 1.05 | 10,500 |
| 2022-06-21 | Trenary C Russell Iii (CEO and President) | Buy | 19,925 | 1.06 | 21,120 |
| 2022-03-01 | Hilzinger Kurt J (Director) | Buy | 27,708 | 1.69 | 46,826 |
| 2022-02-23 | Hilzinger Kurt J (Director) | Buy | 79,535 | 1.44 | 114,530 |
| 2022-02-22 | Hilzinger Kurt J (Director) | Buy | 95,597 | 1.49 | 142,439 |
| 2021-12-06 | Dagnon Terry (Chief Operating Officer) | Buy | 25,201 | 1.38 | 34,777 |
| 2021-12-06 | Trenary C Russell Iii (CEO and President) | Buy | 25,000 | 1.39 | 34,750 |
| 2021-12-03 | Evanson Jeff (Chief Commercial Officer) | Buy | 35,200 | 1.34 | 47,168 |
| 2021-12-03 | Dagnon Terry (Chief Operating Officer) | Buy | 10,000 | 1.42 | 14,200 |
| 2021-12-02 | Haddadin Yezan Munther (Director) | Buy | 10,000 | 1.39 | 13,899 |
| 2021-12-02 | Sukhtian Faisal Ghiath (Director) | Buy | 18,000 | 1.40 | 25,200 |
| 2021-12-02 | Trenary C Russell Iii (CEO and President) | Buy | 10,000 | 1.40 | 14,000 |
| 2021-11-29 | Gms Ventures & Investments | Buy | 16,000,000 | 1.25 | 20,000,000 |
| 2021-04-20 | Kenyon Lawrence A (CEO, Pres, CFO, Treas & Secy) | Buy | 10,000 | 1.83 | 18,300 |
| 2021-04-19 | Haddadin Yezan Munther (Director) | Buy | 10,000 | 1.82 | 18,200 |
| 2021-04-19 | Sukhtian Faisal Ghiath (Director) | Buy | 10,000 | 1.82 | 18,200 |
| 2021-02-23 | Evanson Jeff (Chief Commercial Officer) | Sale | 8,554 | 2.09 | 17,860 |
| 2021-02-23 | Dagnon Terry (Chief Operating Officer) | Sale | 15,900 | 2.09 | 33,199 |
| 2021-02-12 | Evanson Jeff (Chief Commercial Officer) | Sale | 56,973 | 2.55 | 145,281 |
| 2021-02-12 | Dagnon Terry (Chief Operating Officer) | Sale | 63,700 | 2.55 | 162,435 |
| 2021-02-03 | Syntone Ventures Llc | Buy | 3,000,000 | 1.00 | 3,000,000 |
| 2021-02-02 | Gms Ventures & Investments | Buy | 8,360,000 | 1.00 | 8,360,000 |
| 2020-09-22 | Haddadin Yezan Munther (Director) | Buy | 10,000 | .72 | 7,250 |
| 2020-09-17 | Sukhtian Faisal Ghiath (Director) | Buy | 10,000 | .67 | 6,730 |
| 2020-09-14 | Thurman Randy H (Director) | Buy | 10,000 | .62 | 6,200 |
| 2020-07-15 | Syntone Ventures Llc | Buy | 823,045 | 1.22 | 999,999 |
| 2020-03-23 | Sukhtian Ghiath M. | Option Ex | 29,358,621 | .00 | 0 |
| 2020-01-29 | Sukhtian Ghiath M. (Director) | Option Ex | 4,657,852 | .23 | 1,080,621 |
| 2019-12-23 | Sukhtian Ghiath M. (Director) | Option Ex | 2,909,091 | .23 | 674,909 |
| 2019-09-18 | Kenyon Lawrence A (CEO, Pres, CFO, Treas & Secy) | Sale | 1,350 | 1.70 | 2,295 |
| 2019-06-17 | Sukhtian Ghiath M. (Director) | Option Ex | 2,181,818 | .00 | 0 |
| 2019-02-07 | Kenyon Lawrence A (CEO, Pres, CFO, Treas & Secy) | Buy | 25,000 | .90 | 22,375 |
| 2019-02-04 | Hilzinger Kurt J (Director) | Buy | 5,983 | .80 | 4,786 |
| 2019-02-01 | Hilzinger Kurt J (Director) | Buy | 8,200 | .77 | 6,314 |
| 2019-01-31 | Hilzinger Kurt J (Director) | Buy | 6,300 | .75 | 4,725 |
| 2019-01-30 | Hilzinger Kurt J (Director) | Buy | 4,890 | .72 | 3,520 |
| 2019-01-29 | Hilzinger Kurt J (Director) | Buy | 5,400 | .73 | 3,942 |
| 2019-01-28 | Hilzinger Kurt J (Director) | Buy | 15,884 | .71 | 11,277 |
| 2019-01-25 | Hilzinger Kurt J (Director) | Buy | 10,828 | .69 | 7,471 |
| 2019-01-23 | Hilzinger Kurt J (Director) | Buy | 2,266 | .67 | 1,518 |
| 2019-01-22 | Hilzinger Kurt J (Director) | Buy | 10,749 | .68 | 7,309 |
| 2019-01-17 | Hilzinger Kurt J (Director) | Buy | 2,300 | .69 | 1,586 |
| 2019-01-16 | Hilzinger Kurt J (Director) | Buy | 800 | .68 | 544 |
| 2019-01-15 | Mohan Pankaj (Director) | Buy | 8,000 | .68 | 5,440 |
| 2019-01-15 | Hilzinger Kurt J (Director) | Buy | 2,266 | .70 | 1,586 |
| 2019-01-14 | Hilzinger Kurt J (Director) | Buy | 4,399 | .71 | 3,123 |
| 2019-01-10 | Hilzinger Kurt J (Director) | Buy | 6,053 | .70 | 4,237 |
| 2019-01-09 | Hilzinger Kurt J (Director) | Buy | 2,792 | .73 | 2,038 |
| 2019-01-08 | Hilzinger Kurt J (Director) | Buy | 6,410 | .65 | 4,166 |
| 2019-01-07 | Hilzinger Kurt J (Director) | Buy | 5,166 | .63 | 3,254 |
| 2019-01-04 | Hilzinger Kurt J (Director) | Buy | 6,205 | .59 | 3,660 |
| 2019-01-03 | Hilzinger Kurt J (Director) | Buy | 4,200 | .59 | 2,478 |
| 2019-01-02 | Hilzinger Kurt J (Director) | Buy | 1,640 | .59 | 967 |
| 2018-12-31 | Hilzinger Kurt J (Director) | Buy | 11,349 | .59 | 6,695 |
| 2018-12-28 | Hilzinger Kurt J (Director) | Buy | 11,910 | .52 | 6,193 |
| 2018-12-27 | Hilzinger Kurt J (Director) | Buy | 730 | .51 | 372 |
| 2018-12-26 | Hilzinger Kurt J (Director) | Buy | 5,714 | .54 | 3,085 |
| 2018-12-24 | Hilzinger Kurt J (Director) | Buy | 1,113 | .66 | 734 |
| 2018-12-21 | Thurman Randy H (Director) | Buy | 15,000 | .68 | 10,245 |
| 2018-12-21 | Hilzinger Kurt J (Director) | Buy | 3,600 | .65 | 2,340 |
| 2018-09-18 | Kenyon Lawrence A (CEO, Pres, CFO, Treas & Secy) | Sale | 10,100 | .87 | 8,807 |
| 2018-06-25 | Bahrt Kenneth (Chief Medical Officer) | Sale | 7,700 | .84 | 6,506 |
| 2018-01-04 | Mohan Pankaj (President & CEO) | Sale | 62,569 | 1.16 | 72,580 |
| 2018-01-03 | Mohan Pankaj (President & CEO) | Sale | 52,108 | 1.18 | 61,487 |
| 2017-12-22 | Yamashita Elizabeth A. (VP, Regulatory Affairs) | Sale | 16,170 | 1.13 | 18,272 |
| 2017-12-22 | Bahrt Kenneth (Chief Medical Officer) | Sale | 26,165 | 1.13 | 29,566 |
| 2017-12-22 | Kenyon Lawrence A (CFO and Secretary) | Sale | 26,165 | 1.13 | 29,566 |
| 2017-12-22 | Mcandrew Stephen J (SVP Bus. Strat. & Dev.) | Sale | 15,705 | 1.13 | 17,746 |
| 2017-12-19 | Mohan Pankaj (President & CEO) | Sale | 83,608 | 1.14 | 95,313 |
| 2017-12-19 | Yamashita Elizabeth A. (VP, Regulatory Affairs) | Sale | 6,151 | 1.14 | 7,012 |
| 2017-12-18 | Mohan Pankaj (President & CEO) | Sale | 20,523 | 1.17 | 24,011 |
| 2017-12-18 | Yamashita Elizabeth A. (VP, Regulatory Affairs) | Sale | 1,509 | 1.17 | 1,765 |
| 2016-11-23 | Griffith Donald J. | Sale | 1 | 3.75 | 3 |
| 2016-11-11 | Gangloff Scott A. (SVP, Development & Mfrg) | Sale | 37,369 | 3.75 | 140,133 |
| 2016-11-11 | Mcandrew Stephen J (SVP Bus. Strat. & Dev.) | Sale | 21,367 | 3.75 | 80,126 |
| 2016-11-09 | Gangloff Scott A. (SVP, Development & Mfrg) | Option Ex | 115,942 | .00 | 0 |
| 2016-11-09 | Griffith Donald J. | Option Ex | 144,927 | .00 | 0 |
| 2016-11-09 | Brady Todd C | Option Ex | 28,985 | .00 | 0 |
| 2016-11-09 | Canute Scott A | Option Ex | 57,971 | .00 | 0 |
| 2016-11-09 | Mcandrew Stephen J (SVP Bus. Strat. & Dev.) | Option Ex | 57,971 | .00 | 0 |
| 2016-05-13 | Bahrt Kenneth (Chief Medical Officer) | Buy | 2,000 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of OTLK listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Outlook Therapeutics, Inc. (symbol OTLK, CIK number 1649989) see the Securities and Exchange Commission (SEC) website.